Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population.
COVID-19
antibodies
long-lasting immunity
seroconversion
vaccination
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
18 11 2022
18 11 2022
Historique:
received:
05
10
2022
revised:
10
11
2022
accepted:
14
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population. A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test. Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL ( These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
Sections du résumé
BACKGROUND
Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
AIM
This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population.
METHODS
A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test.
RESULTS
Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (
CONCLUSION
These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
Identifiants
pubmed: 36429974
pii: ijerph192215257
doi: 10.3390/ijerph192215257
pmc: PMC9691066
pii:
doi:
Substances chimiques
Spike Glycoprotein, Coronavirus
0
Antibodies, Viral
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Infect Dis. 2021 May 18;72(10):e545-e551
pubmed: 32840287
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Microbiol Spectr. 2021 Sep 3;9(1):e0024721
pubmed: 34190591
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Commun. 2022 Feb 16;13(1):907
pubmed: 35173150
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Lancet Reg Health Am. 2022 Feb;6:100123
pubmed: 34841388
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Clin Infect Dis. 2022 Feb 11;74(3):472-478
pubmed: 33999127
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
JAMA Netw Open. 2021 Aug 2;4(8):e2119741
pubmed: 34357399
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Immun Inflamm Dis. 2022 Jun;10(6):e612
pubmed: 35634960
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
EBioMedicine. 2022 Jan;75:103805
pubmed: 35032961
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Viruses. 2022 Jul 08;14(7):
pubmed: 35891471
Clin Infect Dis. 2022 Aug 24;75(1):e1072-e1081
pubmed: 34609506
Eur J Immunol. 2020 Dec;50(12):2025-2040
pubmed: 33084029
Eur J Immunol. 2022 Jan;52(1):149-160
pubmed: 34695227
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Int J Environ Res Public Health. 2022 Feb 10;19(4):
pubmed: 35206161
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
J Intern Med. 2022 Jan;291(1):32-50
pubmed: 34352148